知镜 Cognispect · 医学文献与研究工作台

Urine sediment (uSed) in molecular diagnosis of genitourinary cancer: From materials to methods

Zhao J, Song X.
J Liq Biopsy · 2026-10-21 · PMID 42985552

文献摘要

Urine sediment (uSed) has often been treated as a residual pellet of urinalysis. Here, we reframe it as a biosource for molecular diagnosis in genitourinary (GU) cancer, yet its promise lies less in the molecules it contains than in the methods that make them interpretable. uSed carries tumor-derived DNA, RNA, proteins, and metabolites that capture genetic, epigenetic, transcriptional, proteomic, and metabolic alterations, enabling early detection, risk stratification, therapeutic monitoring, and minimal residual disease surveillance. Its molecular cargo determines biological reach, whereas analytical methods determine the reliability of clinical readouts. This Materials-to-Methods distinction is essential because the field remains rich in discovery but poor in validation: high diagnostic accuracy is frequently reported, yet few uSed assays are prospective, externally validated, or shown to change clinical management. We therefore synthesize uSed as a distinct urine fraction, separate from whole urine, cell-free supernatant, and extracellular vesicles, and evaluate how pre-analytical variability, analytical rigor, and post-analytical evidence grading determine whether molecular signals become clinically actionable. We propose that uSed research must shift from marker discovery to method-defined clinical utility, integrating standardization, external validation, and multi-omic/artificial intelligence approaches within a single translational framework. In this view, uSed is a complementary biosource for molecular diagnosis, not a substitute for tissue biopsy or established clinical pathways.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。